Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2069
+0.0150 (7.82%)
At close: Jan 22, 2026, 4:00 PM EST
0.2050
-0.0019 (-0.92%)
After-hours: Jan 22, 2026, 8:00 PM EST
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,190,455
Market Cap
7.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 22 | 0 | - | 20 | 2 |
| Dec 31, 2023 | 22 | 1 | 4.76% | 22 | 0 |
| Dec 31, 2022 | 21 | 5 | 31.25% | 21 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 16 | 0 |
| Dec 31, 2020 | 10 | -1 | -9.09% | 10 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genprex | 15 |
| Silexion Therapeutics | 14 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Indaptus Therapeutics | 7 |
| Adial Pharmaceuticals | 5 |
| Creative Medical Technology Holdings | 4 |
| Acurx Pharmaceuticals | 4 |
TOVX News
- 24 days ago - Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - GlobeNewsWire
- 3 months ago - Theriva Biologics Provides Response to Unusual Market Action - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - GlobeNewsWire
- 5 months ago - Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 9 months ago - Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 9 months ago - Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewsWire
- 9 months ago - Theriva Biologics Announces Pricing of $7.5 Million Public Offering - GlobeNewsWire